NAMS
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $22.50M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $22.50M | -50.6% |
| FY 2024 | $45.56M | +223.4% |
| FY 2023 | $14.09M | -86.3% |
| FY 2022 | $102.69M | - |
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $22.50M for fiscal year 2025, as filed in its audited annual report with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.